Netherlands· NL-4528509986a3

Cenrifki 60 mg filmomhulde tabletten

A tolebrutinib product containing tolebrutinib, registered in Netherlands by Sanofi Winthrop Industrie. The same ATC class is registered in 5 of our 19 countries.

ATC L04AA62

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about tolebrutinibAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Tolebrutinib is registered in 5 of 19 countries.

Countries holding a registration under ATC L04AA62 (tolebrutinib), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
4 of them publish a price we can compare per daily dose

Search tolebrutinib products by name

Tolebrutinib · ATC L04AA62

5 / 19 countries

Belgiumprice
Czechiaprice
Finlandprice
Netherlands
Polandprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)

Active substance: TOLEBRUTINIB
Manufacturer: Sanofi Winthrop Industrie
Country: Netherlands (NL)
ATC code: L04AA62
ATC class: Tolebrutinib
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
EU/1/25/2011

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Tolebrutinib in 7 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All tolebrutinib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

Iceland · Cenrifki
Liechtenstein · Cenrifki
Norway · Cenrifki

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/fe733e91-22d2-4fae-8638-d5ad18c89f13
GET /v1/drugs/fe733e91-22d2-4fae-8638-d5ad18c89f13?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/cenrifki-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Tolebrutinib",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp134762",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSPOVIDON (E 1202)",
    "HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
    "IJZEROXIDE GEEL (E 172)",
    "IJZEROXIDE ROOD  (E 172)",
    "LACTOSE 1-WATER",
    "MACROGOL 400",
    "MAGNESIUMSTEARAAT (E 470b)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "TOLEBRUTINIB"
  ],
  "leaflet_url": null,
  "authorised_at": "2026/06/19",
  "procedure_number": "EMEA/H/C/006386",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/25/2011",
  "additional_monitoring": "Y"
}

API reference MCP server Plans

See everything about tolebrutinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console